Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?
Clicks: 289
ID: 12880
Direct oral anticoagulants (DOACs) are now widely used for the management of venous thromboembolism (VTE) that now includes cancer-associated thrombosis. This review summarizes recent data on VTE prophylaxis and treatment, new challenges, guidelines, and updates as well as the current place for DOACs on the emerging cancer-associated VTE management landscape.
| Reference Key |
ramacciottidirectclinical
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Ramacciotti, Eduardo;Agati, Leandro B;Caffaro, Roberto Augusto;Volpiani, Giuliano G;Lopes, Renato D;Comerota, Anthony J;Fareed, Jawed; |
| Journal | clinical and applied thrombosis/hemostasis : official journal of the international academy of clinical and applied thrombosis/hemostasis |
| Year | Year not found |
| DOI | 10.1177/1076029619856433 |
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.